Stocksigma LogoStocksigma Logo

Senores Pharmaceuticals Q2 and H1 FY27 Performance Presentation

Senores Pharmaceuticals reported consolidated revenue growth of 25% YoY to ₹192.3 Cr in Q2 FY27 and 30% YoY to ₹372.5 Cr in H1 FY27

Senores Pharmaceuticals Q2 and H1 FY27 Performance Presentation

Senores Pharmaceuticals Ltd · Investor Presentation · 29 Oct 2026, 8:16 pm

Senores Pharmaceuticals Q2 and H1 FY27 Performance Presentation Senores Pharmaceuticals reported consolidated revenue growth of 25% YoY to ₹192.3 Cr in Q2 FY27 and 30% YoY to ₹372.5 Cr in H1 FY27. Regulated markets drove 71% of H1 revenue with ~42% EBITDA margins. Consolidated H1 EBITDA surged 58.2% YoY to ₹111.4 Cr, expanding margins by ~530 bps to 29.9%, while PAT rose 31% YoY to ₹67.0 Cr. Growth was supported by 64 approved ANDAs and forward integration through Zoraya and Amerisyn, targeted to accelerate H2 FY27 performance across US government and B2C channels.

Original exchange filing (PDF)

More announcements from Senores Pharmaceuticals Ltd

All Senores Pharmaceuticals Ltd announcements